Based on the results of the feasibility program, Ferring will have the option to license the oral tablet formulation from Enteris. This new agreement between Enteris and Ferring adds to several ...

SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ...

intranasal program formulation technology expected to deliver improved central nervous system (CNS) penetration of psychedelic medicines. Mindset is developing several novel families of next ...

Keticap® is an oral immediate-release ketamine formulation intended for the treatment of mood disorders such as treatment-resistant depression (TRD) and bipolar depression. The programme is in a ...

Program within the Department of Defense (DoD) focused on exploring the company’s platform formulation technology for the delivery of prefilled, high-dose formulations for the rapid deployment ...

The program starts with a PoP (Proof of Process) phase. This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (CESS ®2 technology-based ...

The program starts with a PoP (Proof of Process) phase. This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (CESS® 2 technology-based ...